Insurance access tool

GLP-1 Prior Authorization Letter Generator

Two minutes gets you a draft prior authorization letter for Foundayo, Saxenda, Zepbound or Wegovy. It is built from the indication language in the FDA label, whichever pivotal trial citation applies, and the step-therapy documentation most US insurers ask for. Pass the draft to your prescribing clinician; reviewing, editing, signing and submitting are theirs to do.

DRAFT — the prescribing clinician must review and sign this before it is submitted. Not legal or medical advice.

A template letter is what comes out of this generator, for the prescribing clinician to review, edit and sign. No medical advice is given here and no coverage is guaranteed. Your browser generates the letter in full: nothing you type is transmitted or stored.

Computed from your weight + height: 31.9

Documented weight-related comorbidities
Documented prior weight loss attempts

Generated PA letter

[Date]

Aetna Pharmacy Prior Authorization Department
Re: Prior Authorization Request

Patient: [Patient Name]
Date of Birth: [DOB]
Height: 5 ft 8 in
Current Weight: 210 lbs
BMI: 31.9 kg/m²
Requested Medication: Wegovy (semaglutide) 2.4 mg subcutaneous once weekly
Requested Quantity: four (4) single-dose 2.4 mg pens per 28 days

To Whom It May Concern,

This is a request for prior authorization coverage of Wegovy (semaglutide) 2.4 mg subcutaneous once weekly, on behalf of the patient named above, for chronic weight management — an FDA-approved indication.

FDA-Approved Indication. Wegovy (semaglutide) is FDA-approved, alongside a lower-calorie diet and more exercise, to bring excess weight down and keep it down over the long term, in adults who have obesity or who are overweight with at least one weight-related comorbid condition. In the pivotal trials behind the label, obesity meant a BMI of 30 kg/m² or higher and overweight a BMI from 27 up to 30 kg/m²; payer criteria use those same cut-offs. Wegovy is additionally FDA-approved (i) to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, FDA-approved March 2024), and (ii) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (stage F2-F3) in conjunction with diet and physical activity (ESSENCE trial, FDA accelerated approval August 2025). If the patient's primary qualifying condition is established CVD or biopsy/imaging-confirmed MASH with fibrosis, submit under that indication.

Patient Eligibility. At a documented 31.9 kg/m², this patient meets the obesity definition (BMI ≥ 30 kg/m²) used in the label's pivotal trials and in plan criteria. Documented alongside that, this patient carries the following weight-related comorbid condition(s): Type 2 diabetes mellitus (ICD-10 E11.9).

Clinical Rationale. Level 1 evidence out of the STEP-1 pivotal trial supports Wegovy. STEP-1 (Wilding et al., NEJM 2021) demonstrated mean total body weight loss of 14.9% over 68 weeks at the 2.4 mg maintenance dose. Read together, this patient's BMI and their documented comorbid burden put them squarely inside the FDA-approved population that trial studied, and what is requested here is the labeled maintenance dose.

Step Therapy and Prior Treatment History. Ahead of this request the patient has on record the weight management attempts listed below, not one of which produced weight loss that was either sustained or clinically meaningful: supervised reduced-calorie dietary intervention of at least 6 months duration and structured physical activity program of at least 150 minutes per week sustained for 6 months. Together they document the prior-treatment history that step therapy calls for.

Plan-Specific Note. Aetna's pharmacy PA criteria for weight-management GLP-1s set the baseline BMI floor at 30 kg/m² (27 kg/m² where a weight-related comorbidity exists) and look for at least six months in a structured weight-loss program, built on behavior change, calorie reduction and exercise with ongoing follow-up, before medication starts. Both are documented in this letter.

Attestation. On the BMI and comorbidity documentation above, this patient falls within the FDA-approved population and the plan's BMI criteria. This patient was evaluated by me personally, and everything set out above is accurate so far as I know it. Weight, vital signs and adverse effects will go on being monitored per standard of care. I will reassess weight-loss response once the patient is at the maintenance dose and will discontinue therapy if the response does not meet the plan's reauthorization criteria.

Requested Action. Approve Wegovy 2.4 mg subcutaneous once weekly for the plan's initial authorization period, with reauthorization thereafter to turn on documented weight-loss response.

With thanks for reviewing this promptly. Any questions, or any further documentation required, please reach my office.

Sincerely,

[Prescribing Clinician Name, Credentials]
Prescribing Clinician
_________________________________
Signature                                    Date

DRAFT — the prescribing clinician must review and sign this before it is submitted. Not legal or medical advice.

Prior authorization, and why a GLP-1 sets one off

Prior authorization (PA) is a utilization management rule insurers use to control spending on high-cost drugs. For brand GLP-1 weight-loss medications — Wegovy, Zepbound, Saxenda, and the newly approved Foundayo — virtually every US commercial plan requires PA before paying any portion of the prescription. The reason is simple: list prices are as much as $1,349 per monthly fill, so a covered patient on therapy for a year can represent about $17,500 of annual plan spend.

A complete PA submission has to demonstrate three things: (1) the patient is in the FDA-approved population — adults with obesity, or with overweight plus at least one weight-related comorbidity, which plans read as BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with a comorbidity — (2) prior weight management attempts have been documented to satisfy the plan's step-therapy requirement, and (3) the prescribing clinician attests to the clinical rationale and ongoing monitoring plan. The letter generated by this tool covers all three and uses FDA-label language verbatim where possible.

How to use the generator

  1. Pick your insurer from the dropdown.
  2. Choose whichever drug and dose your clinician prescribed.
  3. Enter your weight and height — BMI auto-computes.
  4. Check off any documented comorbidities.
  5. Check off documented prior weight loss attempts (the step-therapy requirement most plans enforce).
  6. Copy the letter and bring it to your prescribing clinician. They will review, edit, sign, and submit it through the insurer's pharmacy benefit portal.

Your browser assembles the letter and nothing leaves it: what you type is neither transmitted nor stored, and no patient information is logged.

Sample PA letter (Wegovy + BMI 32 + Type 2 diabetes + Aetna)

A worked example. The case that arises most often is an Aetna-covered patient at BMI 32, documented Type 2 diabetes, requesting Wegovy 2.4 mg. Every combination of drug, insurer and comorbidity is handled by the live generator above.

[Date]

Aetna Pharmacy Prior Authorization Department
Re: Prior Authorization Request

Patient: [Patient Name]
Date of Birth: [MM/DD/YYYY]
Height: 5 ft 8 in
Current Weight: 210 lbs
BMI: 32.0 kg/m²
Requested Medication: Wegovy (semaglutide) 2.4 mg subcutaneous once weekly
Requested Quantity: four (4) single-dose 2.4 mg pens per 28 days

To Whom It May Concern,

This is a request for prior authorization coverage of Wegovy (semaglutide) 2.4 mg subcutaneous once weekly, on behalf of the patient named above, for chronic weight management — an FDA-approved indication.

FDA-Approved Indication. Wegovy (semaglutide) is FDA-approved, alongside a lower-calorie diet and more exercise, to bring excess weight down and keep it down over the long term, in adults who have obesity or who are overweight with at least one weight-related comorbid condition. In the pivotal trials behind the label, obesity meant a BMI of 30 kg/m² or higher and overweight a BMI from 27 up to 30 kg/m²; payer criteria use those same cut-offs. Wegovy is additionally FDA-approved (i) to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, FDA-approved March 2024), and (ii) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (stage F2-F3) in conjunction with diet and physical activity (ESSENCE trial, FDA accelerated approval August 2025). If the patient's primary qualifying condition is established CVD or biopsy/imaging-confirmed MASH with fibrosis, submit under that indication.

Patient Eligibility. At a documented 32.0 kg/m², this patient meets the obesity definition (BMI ≥ 30 kg/m²) used in the label's pivotal trials and in plan criteria. Documented alongside that, this patient carries the following weight-related comorbid condition(s): Type 2 diabetes mellitus (ICD-10 E11.9).

Clinical Rationale. Level 1 evidence out of the STEP-1 pivotal trial supports Wegovy. STEP-1 (Wilding et al., NEJM 2021) demonstrated mean total body weight loss of 14.9% over 68 weeks at the 2.4 mg maintenance dose. Read together, this patient's BMI and their documented comorbid burden put them squarely inside the FDA-approved population that trial studied, and what is requested here is the labeled maintenance dose.

Step Therapy and Prior Treatment History. Ahead of this request the patient has on record the weight management attempts listed below, not one of which produced weight loss that was either sustained or clinically meaningful: supervised reduced-calorie dietary intervention of at least 6 months duration, structured physical activity program of at least 150 minutes per week sustained for 6 months, and prior trial of phentermine, discontinued for inadequate response or intolerance. Together they document the prior-treatment history that step therapy calls for.

Plan-Specific Note. Aetna's pharmacy PA criteria for weight-management GLP-1s set the baseline BMI floor at 30 kg/m² (27 kg/m² where a weight-related comorbidity exists) and look for at least six months in a structured weight-loss program, built on behavior change, calorie reduction and exercise with ongoing follow-up, before medication starts. Both are documented in this letter.

Attestation. On the BMI and comorbidity documentation above, this patient falls within the FDA-approved population and the plan's BMI criteria. This patient was evaluated by me personally, and everything set out above is accurate so far as I know it. Weight, vital signs and adverse effects will go on being monitored per standard of care. I will reassess weight-loss response once the patient is at the maintenance dose and will discontinue therapy if the response does not meet the plan's reauthorization criteria.

Requested Action. Approve Wegovy 2.4 mg subcutaneous once weekly for the plan's initial authorization period, with reauthorization thereafter to turn on documented weight-loss response.

With thanks for reviewing this promptly. Any questions, or any further documentation required, please reach my office.

Sincerely,

[Prescribing Clinician Name, MD]
Prescribing Clinician
_________________________________
Signature                                    Date

DRAFT — the prescribing clinician must review and sign this before it is submitted. Not legal or medical advice.

Frequently asked questions

What is prior authorization for GLP-1 drugs?

A coverage rule, in short. No plan pays for a brand GLP-1 like Zepbound or Wegovy until your doctor has put clinical documentation in front of the insurer — and nothing else obstructs a brand GLP-1 weight-loss approval as much.

Why is prior auth required for Zepbound and Wegovy?

At list price a brand GLP-1 can run $1,349 a month, and PA is how the insurer satisfies itself on three points before paying: that the FDA label criteria are met, that cheaper weight management came first, and that a clinical rationale is documented. See our GLP-1 insurance coverage audit for how coverage rates actually fall out plan by plan.

How long does prior authorization take?

Most commercial plans process a complete PA submission within 3 to 14 business days. Standard turnaround is about 5 business days; expedited reviews are typically 24 to 72 hours. Incomplete submissions add 1 to 2 weeks of back-and-forth — which is exactly the friction this tool is designed to eliminate.

Does my doctor have to write the PA letter?

Yes — the prescribing clinician is required to author and sign the PA letter; insurers will not accept a letter from the patient. This generator produces a draft template the clinician can review, edit, and sign. See our guide on how to get a GLP-1 prescription.

What if my prior auth is denied?

Appeal — the Affordable Care Act protects that right federally. Denials tend to come down to non-formulary status, no documented prior weight-loss attempts, or missing BMI documentation. Ask for a peer-to-peer review, your doctor to the insurance medical director; it can reverse a denial without a formal appeal.

Does compounded GLP-1 need prior auth?

No. Out of a compounding pharmacy, compounded tirzepatide and semaglutide are paid for out of pocket and never reach your insurance pharmacy benefit, so no PA arises. You forgo insurance coverage for that, and pick up quality and supply risk.

Can I appeal a denial?

Yes — an internal appeal goes to the insurer first, and if it is refused again, an independent external review follows. Federal law allows 180 days from the denial notice for that internal filing. Send the original PA letter along with it, plus further clinical documentation; the case is stronger for both.

How is the BMI requirement enforced?

Insurers verify BMI from the height and weight documented in the most recent clinical visit note. The BMI must be calculated and recorded in the patient's chart before PA submission, not estimated. Wegovy, Zepbound, Saxenda, and Foundayo are all labeled for adults with obesity, or with overweight plus a weight-related comorbidity; plans apply the cut-offs from the pivotal trials, BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with a weight-related comorbidity.

Important disclaimer

What this produces is a draft template, nothing further — not legal advice, not medical advice, and no guarantee that any insurer will cover anything. Nothing goes to an insurer until the prescribing clinician has read, edited and signed it. Where the FDA label supplies wording, that wording is reproduced exactly; where it does not, no clinical recommendation gets invented to fill the gap. GLP Watchdog does not provide medical advice, diagnosis, or treatment recommendations and is not affiliated with any insurer or drug manufacturer.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Novo Nordisk Inc. SAXENDA (liraglutide) injection — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
  4. 4.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  5. 5.Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge — Information for Providers (FAQs). CMS.gov. 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
  6. 6.Aetna. Wegovy PA with Limit 4774-C P08-2025 v5 — Pharmacy Clinical Policy Bulletin (non-Medicare). Aetna. 2026. https://www.aetna.com/products/rxnonmedicare/data/2026/Wegovy_PA_with_Limit_4774-C_P08-2025_v5.html
  7. 7.Cigna. Drug Coverage Policy IP0816 — Zepbound (effective 09/01/2026). Cigna. 2026. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/pharmacy/ip_0816_coveragepositioncriteria_weight_loss_zepbound.pdf
  8. 8.UnitedHealthcare. Prior Authorization/Notification — Weight Loss, Program Number 2026 P 1114-23 (effective 10/1/2026). UnitedHealthcare Pharmacy. 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
  9. 9.Express Scripts (TRICARE pharmacy contractor). GLP-1 Medications (Diabetes and Weight Management) — TRICARE pharmacy benefit FAQ. Express Scripts / TRICARE. 2026. https://militaryrx.express-scripts.com/GLP-1-medications-diabetes-weight-management
  10. 10.American Medical Association. Prior Authorization Reform Initiatives and Physician Documentation Guidance. AMA. 2024. https://www.ama-assn.org/practice-management/prior-authorization
  11. 11.Centers for Medicare & Medicaid Services. Prior Authorization — Healthcare.gov Glossary. Healthcare.gov. 2024. https://www.healthcare.gov/glossary/prior-authorization/
  12. 12.Novo Nordisk. Wegovy cost, coverage and savings resources (NovoCare). Manufacturer Patient Access. 2026. https://www.novocare.com/patient/medicines/wegovy.html

Frequently Asked Questions

It is a coverage rule: before your plan will pay for a brand GLP-1 such as Zepbound or Wegovy, your doctor has to send clinical documentation to the insurer. Nothing else slows down a brand GLP-1 weight-loss approval as much.
List price on a brand GLP-1 runs as high as $1,349 a month, and prior authorization is how an insurer checks three things before paying it: that the patient is in the FDA-approved population (in plan terms, BMI ≥ 30, or BMI ≥ 27 alongside a weight-related comorbidity), that cheaper weight management was tried first, and that a clinical rationale is on the record.
A complete PA submission clears most commercial plans inside 3 to 14 business days, with 5 business days the usual figure. Urgent clinical situations qualify for expedited review, generally 24 to 72 hours. Submit something incomplete and expect another 1 to 2 weeks of back-and-forth.
Yes, and it has to be them: an insurer will not take a PA letter written by the patient, so the prescribing clinician must author and sign it. What this generator gives you is a draft to hand your doctor's office, which speeds that up.
Appeal — the right is federally protected under the Affordable Care Act. Denials usually come down to one of three things: non-formulary status, no documented prior weight-loss attempts, or missing BMI documentation. Ask for a peer-to-peer review, where your doctor speaks to the insurance medical director; it can overturn a denial without a formal appeal.
No. Coming from a compounding pharmacy, compounded tirzepatide and semaglutide are paid out of pocket and never touch your insurance pharmacy benefit, so prior authorization does not arise. What you give up is insurance coverage, and you take on quality and supply risk instead.
Yes — first an internal appeal with the insurer itself, then, if that is refused too, an independent external review. Under federal law you have 180 days from the denial notice to get the internal appeal filed. Attach the original PA letter and whatever further clinical documentation exists; it makes a substantial difference.
The insurer's reference point is whatever height and weight the last clinical visit note happens to record. Estimating will not do: BMI has to be calculated and written into the chart before the PA goes in. Foundayo, Saxenda, Zepbound and Wegovy are all labeled for adults who have obesity, or who are overweight and have a weight-related comorbidity, and plans apply the cut-offs used in their pivotal trials: BMI of 30 kg/m² or more, or 27 kg/m² and above where a weight-related comorbidity is present.
Data freshnessLast verified Cadence: quarterly

Source: Current Wegovy, Zepbound, Saxenda and Foundayo labels on DailyMed; Aetna, Cigna and UnitedHealthcare published prior-authorization policies; the CMS Medicare GLP-1 Bridge FAQ; and the TRICARE pharmacy GLP-1 page, all read October 24, 2026. Anthem, Blue Cross Blue Shield and Kaiser criteria vary by plan and are not published as one document, so check yours with the plan.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

8.2

bmiMD

Starting below a standard dose, with microdose tiers

6.3

WellMedRx

Comparing compounded and brand GLP-1 plans with a published state list